Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study

Developmental Medicine and Child Neurology

Volumn 57, Issue 1, 2015, Pages 60-67

  Riikonen, Raili ^a   Rener Primec, Zvonka ^b   Carmant, Lionel ^c   Dorofeeva, Maria ^d   Hollody, Katalin ^e   Szabo, Ilona ^e   Krajnc, Branka S ^f   Wohlrab, Gabriele ^g   Sorri, Iiris ^h  

^a UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY CHILDREN S HOSPITAL   (Slovenia)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^e UNIVERSITY OF PÉCS   (Hungary)

^f UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^g UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^h KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; VIGABATRIN;

ADOLESCENT; ADULT; CHEMICALLY INDUCED; CHILD; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; FEMALE; HUMAN; INFANT; MALE; MULTICENTER STUDY; PERIMETRY; SPASMS, INFANTILE; TUBEROUS SCLEROSIS; VISION DISORDERS; VISUAL FIELD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTICONVULSANTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFANT; MALE; SPASMS, INFANTILE; TUBEROUS SCLEROSIS; VIGABATRIN; VISION DISORDERS; VISUAL FIELD TESTS; VISUAL FIELDS; YOUNG ADULT;

EID: 84916213592     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/dmcn.12573     Document Type: Article

References (31)

1. Willmore L, Abelson M, Ben-Menachem E, et al. Vigabatrin update 2008. Epilepsia 2009; 50: 163-73.
2. Kälviäinen R, Nousiainen I, Mäntyjärvi M, et al. Vigabatrin, a GABAergic antiepileptic drug, causes concentric visual field defects. Neurology 1999; 53: 922-6.
3. Wild JM, Martinez C, Reinshagen G, et al. Characteristics of a unique visual field defect. Neurology 1999; 40: 1784-94.
4. Maguire M, Hemming K, Wild J, et al. Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review. Epilepsia 2010; 51: 2423-31.
5. Pellock J, Faught E, Sergott R, et al. Registry initiated to characterize vision loss associated with vigabatrin therapy. Epilepsy Behav 2011; 22: 710-7.
6. Gaily E, Jonsson H, Lappi M. Visual field defects at school-age in children treated with vigabatrin in infancy. Epilepsia 2009; 50: 206-16.
7. Wild J, Chiron C, Ahn H, et al. Visual field loss in patients with refractory partial epilepsy treated with vigabatrin final results from open-label, observational, multicentre study. CNS Drugs 2009; 23: 206-82.
8. Moskowitz A, Hansen R, Eklund S, et al. Electroretinographic (ERG) responses in paediatric patients using vigabatrin. Doc Ophthalmol 2012; 124: 197-209.
9. Kjellström UI, Andréasson S, Ponjavic V. Attenuation of the retinal nerve fibre layer and reduced retinal function assessed by optical coherence tomography and full-field electroretinography in patients exposed to vigabatrin medication. Acta Ophthalmol 2014; 92: 149-57.
10. Hardus P, Verduin W, Berensschot T, et al. The value of electrophysiology results in patients with epilepsy and vigabatrin associated visual field loss. Acta Ophthalmol Scand 2001; 79: 169-74.
11. Vanhatalo S, Nousiainen I, Eriksson K, et al. Visual field constriction in 91 Finnish children treated with vigabatrin. Epilepsia 2002; 43: 748-56.
12. Heim MK, Gidal BE. Vigabatrin-associated retinal damage - potential biochemical mechanisms. Acta Neurol 2012; 126: 219-28.
13. Conway M, Cubbidge R, Hosking S. Visual severity indices demonstrate dose-dependent visual loss from vigabatrin therapy. Epilepsia 2008; 49: 16.
14. Kinirons P, Cavalleri G, Singh R, et al. A pharmacogenetic exploration of vigabatrin-induced visual field constriction. Epilepsy Res 2006; 70: 144-52.
15. McCoy B, Wright T, Weiss S, et al. Electroretinogram changes in a paediatric population with epilepsy, is vigabatrin acting alone? J Child Neurol 2011; 26: 729-33.
16. Sorri I, Brigell MG, Mályusz M, et al. Is reduced ornithine-δ-aminotransferase activity the cause of vigabatrin-associated visual field defects? Epilepsy Res 2010; 92: 48-53.
17. Jammoul F, Degardin J, Pain D, et al. Taurine deficiency damages photoreceptors and retinal ganglion cells in vigabatrin-treated neonatal rats. Mol Cell Neurosci 2010; 43: 414-21.
18. Sills GJ, Patsalos PN, Butler E, et al. Visual field constriction: accumulation of vigabatrin but not tiagabine in the retina. Neurology 2001; 57: 196-200.
19. Hammoudi D, Lee S, Madison A, et al. Reduced visual function associated with infantile spasms in children with vigabatrin therapy. Invest Ophthalmol Vis Sci 2005; 46: 514-20.
20. Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 2007; 48: 1223-44.
21. Sorri I, Rissanen E, Mäntyjärvi M, et al. Visual function in epilepsy patients treated with initial valproate monotherapy. Seizure 2005; 14: 367-70.
22. Krauss GL, Johnson MA, Sheth S, et al. A controlled study comparing visual function in patients treated with vigabatrin and tiagabine. J Neurol Neurosurg Psychiatry 2003; 74: 339-43.
23. Wenzel D. Evoked potentials in infantile spasms. Brain Dev 1987; 9: 365-8.
24. Airaksinen E, Tuomisto L, Riikonen R. The concentrations of GABA, 5-HIAA and HVA in the cerebrospinal fluid of children with infantile spasms and effects of ACTH treatment. Brain Dev 1992; 14: 386-90.
25. Wang Q, Jammoul F, Duboc A, et al. Treatment of epilepsy: the GABA-transaminase inhibitor, vigabatrin, induces neuronal plasticity in the mouse retina. Eur J Neurosci 2008; 27: 2177-87.
26. Elterman R, Shields W, Mansfield K, et al. Randomized trial of vigabatrin in patients with infantile spasms. Neurology 2001; 57: 1416-21.
27. Elterman R, Shields D, Bittman R, et al. Vigabatrin for the treatment of infantile spasms: final report of a randomized trial. J Child Neurol 2010; 25: 1340-7.
28. Chiron C, Dulac O, Beaumont D, et al. Therapeutic trial of vigabatrin in refractory infantile spasms. J Child Neurol 1991; Suppl 2:S52-9.
29. Nabbout R, Chiron C, Mumford J, et al. Vigabatrin in partial seizures in children. J Child Neurol 1997; 12: 172-7.
30. Lux A, Edwards S, Hancock E, et al. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomized trial. Lancet Neurol 2005; 4: 712-7.
31. Go C, MacKay M, Weiss S, et al. Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2012; 78: 1974-80.